Search

Displaying results 4591 - 4600 of 10000 in total
  1. Drug

    Tetroxoprim

    go.drugbank.com/drugs/DB15976
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    AME-527

    go.drugbank.com/drugs/DB05879
    Experimental

    AME-527 is a humanized monoclonal antibody that recognizes human TNF-alpha (hTNF-alpha) with high affinity and specificity.

  3. Drug

    Vusolimogene oderparepvec

    go.drugbank.com/drugs/DB23008
    ApprovedInvestigational

    [L64061] It is administered by direct injection into superficial, deep, or visceral tumors. … Vusolimogene oderparepvec-wtpg is a genetically modified herpes simplex virus type 1 (HSV-1) oncolytic viral therapy used, in combination with [nivolumab], to treat advanced melanoma.

  4. Drug

    ORG-34517

    go.drugbank.com/drugs/DB05423
    Investigational

    It has potential to treat a number of diseases such as Cushing’s disease, hypertension, diabetes, glaucoma etc, in which the activity of metabolites corticosterone and cortisol is high. … ORG-34517 is currently under investigation by Organon for the treatment of depression.

  5. Drug

    Propacetamol

    go.drugbank.com/drugs/DB09288
    Investigational

    Propacetamol is a parenteral formulation of paracetamol and thus, it is a prodrug that is completely hydrolyzed to paracetamol. … [A7892] It is not available in the United States but this prodrug has been widely used in other countries such as France since 1985.[L1505]

  6. Drug

    GI-5005

    go.drugbank.com/drugs/DB05942
    Investigational

    Tarmogens are believed to activate both an innate immune response via Toll-like receptors (TLRs), as well as an adaptive, antigen specific cellular immune response. … GI-5005 is whole, heat-killed recombinant yeast genetically modified to express HCV-specific protein targets.

    Categories: Complex Mixtures
  7. Drug

    Nedaplatin

    go.drugbank.com/drugs/DB13145
    ApprovedInvestigational

    Nedaplatin is a second generation platinum analog [A20300]. It is less nephrotoxic than [DB00515] but has proven equally effective. It was approved for use in Japan in 1995.

  8. Drug

    Davamotecan pegadexamer

    go.drugbank.com/drugs/DB05899
    Investigational

    EP0057 is a conjugate of Insert's proprietary drug delivery molecule, Cyclosert, and the potent anti-cancer compound [camptothecin].

  9. Drug

    Morniflumate

    go.drugbank.com/drugs/DB09285
    Investigational

    Morniflumate is a non-steroidal anti-inflammatory drug with antipyretic properties. It is the morpholinoethyl ester of niflumic acid [L1496].

  10. Drug

    Trastuzumab emtansine

    go.drugbank.com/drugs/DB05773
    ApprovedInvestigational

    Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic … Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity.